Search results | preclinical

Reports

Sensory Organ Partnering Terms and Agreements

The Sensory Organ Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter sensory organ partnering deals.

Public Health Partnering Terms and Agreements

The Public Health Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter public health partnering deals.

Ophthalmics Partnering Terms and Agreements

The Ophthalmics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter ophthalmics/ophthalmology partnering deals.

Hospital Care Partnering Terms and Agreements

The Hospital Care artnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter hospital care partnering deals.

Genetic Disorders Partnering Terms and Agreements

The Genetic Disorders Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter genetic disorders partnering deals.

Dermatology Partnering Terms and Agreements

The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals

Trends in Therapeutic Partnering

The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014.

Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

The Preclinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter preclinical stage licensing/business development and other forms of partnering arrangement.

Insights

Preclinical stage partnering – recent trends 2009 to 2014

Recent trends in preclinical partnering for the top pharma and biotech companies reviewed, over 2,000 deals analyzed – including summary of biopharma deal financials

Discovery, Preclinical and Clinical Stage – recent trends in pharma and biotech partnering 2009 to 2014

Discovery, preclinical and clinical stage pharma and biotech partnering forms a critical part of the drug candidate commercialization process.

Preclinical stage partnering

Preclinical stage partnering refers to a commercial deal or alliance signed when a compound or product…

Charles River Laboratories hunts for M&A

M&A hunt: Speaking at the Leerink Swann Global Healthcare Conference last week, James Foster, chief executive officer of Charles River Laboratories, indicated the company was actively looking for merger and acquisition targets in 2015.

Genmab: Partnering activity 2009-2014

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment.

MorphoSys: Partnering activity 2009-2014

MorphoSys, a leader in antibody drug discovery, has emerged as a top 50 big biotech company with its product pipeline and partnering strategy.

Current Agreements Deal Analysis Update : September 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in August 2014.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Pharma and biotech clinical stage partnering – recent trends 2009 to 2014

Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials

Discovery stage in pharma and biotech partnering – Trends from 2009 to 2014

Numerous pharma and biotech partnering deals have been signed at the discovery stage over the past few years; discovery stage deals remain the most popular stage at which deals are announced.

Events

Sorry, your search returned no results.


Deals

Pfizer and HemoShear to develop predictive model for preclinical drug-induced vascular injury

HemoShear announced a multi-year platform collaboration with Pfizer

Instem chosen for global deployment of Provantis SaaS; Roche consolidates preclinical software systems

Roche has purchased Instem’s Provantis Preclinical solution suite using its SaaS delivery model. 

Transition Therapeutics and Eli Lilly in licensing deal for series of preclinical compounds

Transition will receive exclusive worldwide rights to develop and potentially commercialize a class of compounds that, in preclinical diabetes models showed potential to provide glycemic control and other beneficial effects including weight loss.

WuXi PharmaTech in collaboration with Johnson & Johnson Pharmaceutical R&D for preclinical services and training

WuXi PharmaTech will become a provider of toxicology and other non-clinical services to JANSSEN. In addition, JANSSEN will provide training and other services, reimbursed by WuXi, to establish the GLP quality system and technical capabilities to meet the international standards at WuXi’s toxicology facility in Suzhou, China.

EMD Serono and University of Texas MD Anderson Cancer Center in collaboration for preclinical research, clinical trials

The agreement is set for three years with the potential to renew the alliance. Both parties decided not to disclose financial details.

UCB and Wilex AG enter strategic alliance to develop preclinical oncology portfolio

WILEX will acquire world-wide rights to develop UCB’s entire preclinical oncology portfolio, comprising two small-molecule programmes and three antibody programmes.

Roche and Curevac partner for IDO1 and TDO inhibitors

Curadev Pharma has entered into a research collaboration and license agreement with Roche for development and commercialization of IDO1 and TDO inhibitors

True North Therapeutics banks $32mn series B

True North Therapeutics has completed a $35 million Series B equity financing

Kura Oncology licenses tipifarnib; banks $60 million financing

Kura Oncology has entered into an agreement with Janssen Pharmaceutica for an exclusive license to develop and commercialize tipifarnib in the field of oncology

Arrowhead acquires Novartis RNAi R&D portfolio

Arrowhead Research announced the acquisition of Novartis’ entire RNAi research and development portfolio and associated assets

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif